Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).

Inclusion Criteria:

• Patient has been treatet transaxillary (TAX) with Myval transcatheter aortic valve replacement
• BMI <35 kg/m2
• Ability to give informed consent

Exclusion Criteria:

• History of coronary artery bypass graft and a patent left internal mammary artery (LIMA)
• Age ≤18 years
• Patients presenting with pregnancy
• Patients without informed consent
• Expected life expectancy <2 years

Patients who were treated with Myval TAVR via TAX access are included in the registry.

The participating centers also provide a retrospective cohort of TAX-TAVR implantations with other TAVR prothesis (e.g. Edwards Sapien XT/3/Ultra, Medtronic Evolut R/Pro, Accurate Neo, Allegra, Portico) to compare the results and outcomes of the MYVAL-TAX-TAVR registry using the Myval THV with other TAVR bioprothesis used for TAX-TAVR. To further improve comparability between groups propensity score matching between the groups will be performed using the following parameters (age, sex, STS score, peripheral artery disease, atrial fibrillation, minimum axillary diameter, moderate/severe axillary tortuosity and moderate/severe axillary, calcification).